| Literature DB >> 26507681 |
Ghasem Ghalamfarsa1, Mahmoud Mahmoudi2, Mousa Mohammadnia-Afrouzi3, Yaghoub Yazdani4, Enayat Anvari5, Abolghasem Hadinia1, Amir Ghanbari1, Maryam Setayesh6, Mehdi Yousefi7,8, Farhad Jadidi-Niaragh9.
Abstract
Cytokines are considered important factors in the modulation of various immune responses. Among them, interleukin (IL)-21 is one of the major immune modulators, adjusting various immune responses by affecting various immune cells. It has been suggested that IL-21 may enhance autoimmunity through different mechanisms, such as development and activation of helper T (TH)-17 and follicular helper T (TFH) cells, activation of natural killer (NK) cells, enhancing B-cell differentiation and antibody secretion and suppression of regulatory T (Treg) cells. Moreover, IL-21 has also been suggested to be an inducer of autoimmunity when following treatment of MS patients with some therapeutics such as alemtuzumab. This review will seek to clarify the precise role of IL-21/IL-21R in the pathogenesis of MS and, in its animal model, experimental autoimmune encephalomyelitis (EAE).Entities:
Keywords: IL-21 receptor; Interleukin (IL)-21; multiple sclerosis; pathogenesis
Mesh:
Substances:
Year: 2015 PMID: 26507681 DOI: 10.3109/1547691X.2015.1089343
Source DB: PubMed Journal: J Immunotoxicol ISSN: 1547-691X Impact factor: 3.000